I agree Doolen:
If i were to write a report, I would rate the stock a buy precisely because of the great # of opportunities [catalysts] to provide nice upside to the $80-$82 pt. I believe POM filings [Europe and US] are baked in, but approvals [Rev and Abraxane] and data readouts [apremilast + many others] are the ones to pop the stock. With an accelerated Pom filing in US soon, could we be looking @ a FDA decision in 2012 on it? the approval pops the stock and even chatter leading up to it.
I'd keep the PT low to be 'conservative' -- like typical CELG guidance [ha!]
And completely agree... Many of the catalysts are NON Revlimid... which provide a stronger basis for P/E expansion.
Look forward to the next 21 months full of catalysts.